Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating proteins at baseline to identify potential biomarkers and to understand...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Arends, Rosalinda, Guo, Xiang, Baverel, Paul G., González-García, Ignacio, Xie, James, Morsli, Nassim, Yovine, Alejandro, Roskos, Lorin K.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993189/
https://ncbi.nlm.nih.gov/pubmed/33796405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1898104
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados